Does the media favor ASND or RVMD?

In the previous week, Revolution Medicines had 4 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 9 mentions for Revolution Medicines and 5 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.47 beat Revolution Medicines' score of 0.38 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Revolution Medicines 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ASND or BIIB?

Biogen has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascendis Pharma A/S $814.57M 17.55 -$258M $12.89 17.78 Biogen $9.89B 3.37 $1.29B $5.65 39.95

Does the media refer more to ASND or BIIB?

In the previous week, Biogen had 10 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 15 mentions for Biogen and 5 mentions for Ascendis Pharma A/S. Biogen's average media sentiment score of 0.48 beat Ascendis Pharma A/S's score of 0.47 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biogen 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor ASND or ALNY?

In the previous week, Alnylam Pharmaceuticals had 14 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 19 mentions for Alnylam Pharmaceuticals and 5 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.47 beat Alnylam Pharmaceuticals' score of 0.35 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alnylam Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ASND or ROIV?

In the previous week, Roivant Sciences had 4 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 9 mentions for Roivant Sciences and 5 mentions for Ascendis Pharma A/S. Roivant Sciences' average media sentiment score of 0.83 beat Ascendis Pharma A/S's score of 0.47 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BNTX or ASND?

In the previous week, BioNTech had 24 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 29 mentions for BioNTech and 5 mentions for Ascendis Pharma A/S. BioNTech's average media sentiment score of 0.52 beat Ascendis Pharma A/S's score of 0.47 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 11 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Ascendis Pharma A/S (ASND) Competitors

$229.23 +6.54 (+2.94%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$229.14 -0.09 (-0.04%)

As of 10/9/2026 07:30 PM Eastern

Compare

ASND vs. RVMD, BIIB, ALNY, ROIV, and BNTX

Should you buy Ascendis Pharma A/S stock or one of its competitors? Ascendis Pharma A/S's main competitors and comparable companies include Revolution Medicines (RVMD), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Roivant Sciences (ROIV), and BioNTech (BNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ascendis Pharma A/S compare to Revolution Medicines?

Ascendis Pharma A/S (NASDAQ:ASND) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Ascendis Pharma A/S currently has a consensus price target of $313.21, suggesting a potential upside of 36.64%. Revolution Medicines has a consensus price target of $234.76, suggesting a potential upside of 23.72%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Revolution Medicines had 4 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 9 mentions for Revolution Medicines and 5 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.47 beat Revolution Medicines' score of 0.38 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ascendis Pharma A/S has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

94.3% of Revolution Medicines shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ascendis Pharma A/S has a net margin of 70.99% compared to Revolution Medicines' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Revolution Medicines	N/A	-88.20%	-57.85%

Ascendis Pharma A/S has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.55	-$258M	$12.89	17.78
Revolution Medicines	$11.58M	3,512.36	-$1.13B	-$8.82	N/A

Summary

Ascendis Pharma A/S beats Revolution Medicines on 11 of the 16 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Biogen?

Ascendis Pharma A/S (NASDAQ:ASND) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Ascendis Pharma A/S has a net margin of 70.99% compared to Biogen's net margin of 8.32%. Ascendis Pharma A/S's return on equity of 32.54% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Biogen	8.32%	11.18%	6.88%

87.9% of Biogen shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Biogen has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.55	-$258M	$12.89	17.78
Biogen	$9.89B	3.37	$1.29B	$5.65	39.95

In the previous week, Biogen had 10 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 15 mentions for Biogen and 5 mentions for Ascendis Pharma A/S. Biogen's average media sentiment score of 0.48 beat Ascendis Pharma A/S's score of 0.47 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biogen	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Ascendis Pharma A/S currently has a consensus target price of $313.21, indicating a potential upside of 36.64%. Biogen has a consensus target price of $231.07, indicating a potential upside of 2.38%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, equities research analysts clearly believe Ascendis Pharma A/S is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

Ascendis Pharma A/S has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Biogen has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Biogen on 10 of the 16 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Alnylam Pharmaceuticals?

Ascendis Pharma A/S (NASDAQ:ASND) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

Alnylam Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.55	-$258M	$12.89	17.78
Alnylam Pharmaceuticals	$3.71B	8.38	$313.75M	$5.38	43.25

Ascendis Pharma A/S has a net margin of 70.99% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Ascendis Pharma A/S has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

Ascendis Pharma A/S currently has a consensus price target of $313.21, indicating a potential upside of 36.64%. Alnylam Pharmaceuticals has a consensus price target of $366.65, indicating a potential upside of 57.58%. Given Alnylam Pharmaceuticals' higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Alnylam Pharmaceuticals had 14 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 19 mentions for Alnylam Pharmaceuticals and 5 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.47 beat Alnylam Pharmaceuticals' score of 0.35 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alnylam Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alnylam Pharmaceuticals beats Ascendis Pharma A/S on 9 of the 17 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Roivant Sciences?

Ascendis Pharma A/S (NASDAQ:ASND) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Ascendis Pharma A/S has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.55	-$258M	$12.89	17.78
Roivant Sciences	$8.26M	3,099.16	-$299.77M	-$0.53	N/A

Ascendis Pharma A/S has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Ascendis Pharma A/S presently has a consensus target price of $313.21, indicating a potential upside of 36.64%. Roivant Sciences has a consensus target price of $45.64, indicating a potential upside of 28.77%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Ascendis Pharma A/S has a net margin of 70.99% compared to Roivant Sciences' net margin of -3,534.96%. Ascendis Pharma A/S's return on equity of 32.54% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

64.8% of Roivant Sciences shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Roivant Sciences had 4 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 9 mentions for Roivant Sciences and 5 mentions for Ascendis Pharma A/S. Roivant Sciences' average media sentiment score of 0.83 beat Ascendis Pharma A/S's score of 0.47 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Roivant Sciences on 11 of the 16 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Ascendis Pharma A/S (NASDAQ:ASND) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

BioNTech presently has a consensus target price of $125.69, indicating a potential upside of 29.63%. Ascendis Pharma A/S has a consensus target price of $313.21, indicating a potential upside of 36.64%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.65
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00

Ascendis Pharma A/S has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.55	-$1.29B	-$7.83	N/A
Ascendis Pharma A/S	$814.57M	17.55	-$258M	$12.89	17.78

BioNTech has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Ascendis Pharma A/S has a net margin of 70.99% compared to BioNTech's net margin of -63.54%. Ascendis Pharma A/S's return on equity of 32.54% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

In the previous week, BioNTech had 24 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 29 mentions for BioNTech and 5 mentions for Ascendis Pharma A/S. BioNTech's average media sentiment score of 0.52 beat Ascendis Pharma A/S's score of 0.47 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	11 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.5% of BioNTech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Ascendis Pharma A/S beats BioNTech on 11 of the 16 factors compared between the two stocks.

Get Ascendis Pharma A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASND vs. The Competition

Export

Metric	Ascendis Pharma A/S	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.30B	$3.93B	$7.25B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	17.78	13.55	275.01	26.14
Price / Sales	17.55	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	-77.18	17.17	11.22	6.33
Net Income	-$258M	-$22.69M	$3.50B	$382.15M
7 Day Performance	0.60%	-1.34%	-0.89%	-1.40%
1 Month Performance	-13.01%	-8.04%	-4.02%	-3.35%
1 Year Performance	9.39%	14.18%	7.13%	1.49%

Ascendis Pharma A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASND Ascendis Pharma A/S	4.7957 of 5 stars	$229.23 +2.9%	$313.21 +36.6%	+9.4%	$14.30B	$814.57M	17.78	1,189	Analyst Upgrade
RVMD Revolution Medicines	3.011 of 5 stars	$207.68 +0.5%	$234.33 +12.8%	+293.4%	$44.29B	N/A	N/A	883	Analyst Forecast
BIIB Biogen	3.0323 of 5 stars	$223.59 +1.7%	$230.14 +2.9%	+54.0%	$32.49B	$9.89B	39.57	7,500	Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.4305 of 5 stars	$219.89 +0.1%	$366.90 +66.9%	-49.4%	$29.40B	$3.71B	40.87	2,770	News Coverage Analyst Forecast Insider Trade
ROIV Roivant Sciences	2.9775 of 5 stars	$35.78 +0.2%	$45.64 +27.5%	+120.9%	$25.80B	$8.26M	N/A	721

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASND) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ascendis Pharma A/S (ASND) Competitors

ASND vs. RVMD, BIIB, ALNY, ROIV, and BNTX

How does Ascendis Pharma A/S compare to Revolution Medicines?

Summary

How does Ascendis Pharma A/S compare to Biogen?

Summary

How does Ascendis Pharma A/S compare to Alnylam Pharmaceuticals?

Summary

How does Ascendis Pharma A/S compare to Roivant Sciences?

Summary

How does Ascendis Pharma A/S compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASND vs. The Competition

Ascendis Pharma A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ascendis Pharma A/S (ASND) Competitors

ASND vs. RVMD, BIIB, ALNY, ROIV, and BNTX

How does Ascendis Pharma A/S compare to Revolution Medicines?

Do analysts prefer ASND or RVMD?

Does the media favor ASND or RVMD?

Which has more volatility and risk, ASND or RVMD?

Do insiders and institutionals hold more shares of ASND or RVMD?

Is ASND or RVMD more profitable?

Which has higher valuation and earnings, ASND or RVMD?

Summary

How does Ascendis Pharma A/S compare to Biogen?

Is ASND or BIIB more profitable?

Do insiders and institutionals believe in ASND or BIIB?

Which has stronger earnings & valuation, ASND or BIIB?

Does the media refer more to ASND or BIIB?

Do analysts prefer ASND or BIIB?

Which has more risk and volatility, ASND or BIIB?

Summary

How does Ascendis Pharma A/S compare to Alnylam Pharmaceuticals?

Which has higher valuation & earnings, ASND or ALNY?

Is ASND or ALNY more profitable?

Which has more risk and volatility, ASND or ALNY?

Do analysts prefer ASND or ALNY?

Do institutionals and insiders believe in ASND or ALNY?

Does the media favor ASND or ALNY?

Summary

How does Ascendis Pharma A/S compare to Roivant Sciences?

Which has better earnings and valuation, ASND or ROIV?

Which has more volatility & risk, ASND or ROIV?

Do analysts recommend ASND or ROIV?

Is ASND or ROIV more profitable?

Do insiders and institutionals have more ownership in ASND or ROIV?

Does the media favor ASND or ROIV?

Summary

How does Ascendis Pharma A/S compare to BioNTech?

Do analysts recommend BNTX or ASND?

Which has preferable earnings & valuation, BNTX or ASND?

Which has more risk and volatility, BNTX or ASND?

Is BNTX or ASND more profitable?

Does the media prefer BNTX or ASND?

Do institutionals & insiders believe in BNTX or ASND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASND vs. The Competition

Ascendis Pharma A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools